![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HERC4 |
Gene summary for HERC4 |
![]() |
Gene information | Species | Human | Gene symbol | HERC4 | Gene ID | 26091 |
Gene name | HECT and RLD domain containing E3 ubiquitin protein ligase 4 | |
Gene Alias | HERC4 | |
Cytomap | 10q21.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q5GLZ8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26091 | HERC4 | CCI_1 | Human | Cervix | CC | 2.81e-02 | 7.78e-01 | 0.528 |
26091 | HERC4 | CCI_2 | Human | Cervix | CC | 3.77e-12 | 1.46e+00 | 0.5249 |
26091 | HERC4 | CCI_3 | Human | Cervix | CC | 4.98e-03 | 5.54e-01 | 0.516 |
26091 | HERC4 | sample3 | Human | Cervix | CC | 7.36e-03 | 1.91e-01 | 0.1387 |
26091 | HERC4 | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.46e-26 | -6.42e-01 | 0.0155 |
26091 | HERC4 | HTA11_347_2000001011 | Human | Colorectum | AD | 9.28e-04 | 4.56e-01 | -0.1954 |
26091 | HERC4 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.45e-06 | -5.19e-01 | -0.1207 |
26091 | HERC4 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.07e-03 | -5.58e-01 | -0.2061 |
26091 | HERC4 | HTA11_866_3004761011 | Human | Colorectum | AD | 9.39e-10 | -5.28e-01 | 0.096 |
26091 | HERC4 | HTA11_9408_2000001011 | Human | Colorectum | AD | 2.02e-02 | -7.52e-01 | 0.0451 |
26091 | HERC4 | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.35e-02 | -4.81e-01 | 0.0528 |
26091 | HERC4 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.04e-11 | -4.21e-01 | 0.0674 |
26091 | HERC4 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.49e-05 | -3.09e-01 | 0.294 |
26091 | HERC4 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.01e-24 | -6.25e-01 | 0.3005 |
26091 | HERC4 | F007 | Human | Colorectum | FAP | 3.93e-03 | -2.42e-01 | 0.1176 |
26091 | HERC4 | A001-C-207 | Human | Colorectum | FAP | 3.64e-03 | -2.21e-01 | 0.1278 |
26091 | HERC4 | A015-C-203 | Human | Colorectum | FAP | 3.61e-34 | -6.42e-01 | -0.1294 |
26091 | HERC4 | A015-C-204 | Human | Colorectum | FAP | 8.21e-08 | -3.27e-01 | -0.0228 |
26091 | HERC4 | A014-C-040 | Human | Colorectum | FAP | 4.67e-09 | -5.74e-01 | -0.1184 |
26091 | HERC4 | A002-C-201 | Human | Colorectum | FAP | 2.60e-22 | -5.16e-01 | 0.0324 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0045879 | Thyroid | PTC | negative regulation of smoothened signaling pathway | 17/5968 | 32/18723 | 1.02e-02 | 4.11e-02 | 17 |
GO:00458791 | Thyroid | ATC | negative regulation of smoothened signaling pathway | 20/6293 | 32/18723 | 7.67e-04 | 4.24e-03 | 20 |
GO:0008589 | Thyroid | ATC | regulation of smoothened signaling pathway | 40/6293 | 81/18723 | 2.36e-03 | 1.10e-02 | 40 |
GO:0007224 | Thyroid | ATC | smoothened signaling pathway | 60/6293 | 138/18723 | 9.75e-03 | 3.57e-02 | 60 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041202 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041203 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041204 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa041205 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa041206 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
hsa041207 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
hsa041208 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
hsa041209 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HERC4 | SNV | Missense_Mutation | novel | c.379N>T | p.Val127Leu | p.V127L | Q5GLZ8 | protein_coding | tolerated(0.08) | benign(0.085) | TCGA-22-1012-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HERC4 | SNV | Missense_Mutation | novel | c.1357N>T | p.Thr453Ser | p.T453S | Q5GLZ8 | protein_coding | tolerated(1) | benign(0) | TCGA-77-A5G8-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HERC4 | SNV | Missense_Mutation | novel | c.2360N>C | p.Lys787Thr | p.K787T | Q5GLZ8 | protein_coding | tolerated(0.37) | benign(0.038) | TCGA-77-A5GH-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HERC4 | SNV | Missense_Mutation | novel | c.2101G>A | p.Val701Met | p.V701M | Q5GLZ8 | protein_coding | tolerated(0.23) | benign(0.243) | TCGA-94-A4VJ-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HERC4 | SNV | Missense_Mutation | novel | c.782G>T | p.Gly261Val | p.G261V | Q5GLZ8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CR-7388-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
HERC4 | SNV | Missense_Mutation | novel | c.2857N>A | p.Glu953Lys | p.E953K | Q5GLZ8 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-H7-8501-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | unknown | CR |
HERC4 | SNV | Missense_Mutation | novel | c.1325N>T | p.Ala442Val | p.A442V | Q5GLZ8 | protein_coding | tolerated(0.28) | benign(0.003) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
HERC4 | SNV | Missense_Mutation | c.1765N>G | p.Phe589Val | p.F589V | Q5GLZ8 | protein_coding | tolerated(0.27) | benign(0.017) | TCGA-BR-8589-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
HERC4 | SNV | Missense_Mutation | c.2418N>G | p.Ile806Met | p.I806M | Q5GLZ8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
HERC4 | SNV | Missense_Mutation | c.2870N>C | p.Glu957Ala | p.E957A | Q5GLZ8 | protein_coding | tolerated(0.45) | benign(0.062) | TCGA-CD-A48C-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |